Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by UniSuper Management Pty Ltd

UniSuper Management Pty Ltd lessened its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 93.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 21,700 shares of the company’s stock after selling 287,473 shares during the quarter. UniSuper Management Pty Ltd’s holdings in Teva Pharmaceutical Industries were worth $478,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Wilmington Savings Fund Society FSB purchased a new stake in Teva Pharmaceutical Industries in the 3rd quarter valued at approximately $50,000. Ameliora Wealth Management Ltd. purchased a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter valued at $66,000. IFP Advisors Inc boosted its stake in shares of Teva Pharmaceutical Industries by 96.1% during the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company’s stock valued at $88,000 after acquiring an additional 1,960 shares during the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new stake in Teva Pharmaceutical Industries during the 4th quarter worth about $104,000. Finally, Assetmark Inc. raised its stake in Teva Pharmaceutical Industries by 1,370.3% in the 4th quarter. Assetmark Inc. now owns 5,205 shares of the company’s stock valued at $115,000 after purchasing an additional 4,851 shares during the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. Barclays lowered their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, January 30th. Bank of America lowered their target price on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday, March 6th. Piper Sandler increased their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, January 17th. UBS Group decreased their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a report on Thursday, January 30th. Finally, StockNews.com lowered Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Thursday, March 27th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $23.43.

Teva Pharmaceutical Industries Price Performance

Shares of Teva Pharmaceutical Industries stock opened at $15.39 on Tuesday. The business’s fifty day moving average price is $17.08 and its 200 day moving average price is $18.11. Teva Pharmaceutical Industries Limited has a twelve month low of $12.51 and a twelve month high of $22.80. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. The stock has a market capitalization of $17.44 billion, a P/E ratio of -10.61, a PEG ratio of 1.44 and a beta of 0.82.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. As a group, research analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.